# Zealand Pharma and Generate Biomedicines Partner on AI Obesity Drugs in $1.2B Deal

- URL: https://stocks.freetheai.org/news/zealand-pharma-and-generate-biomedicines-partner-on-ai-obesity-drugs-in-1-2b-726e1c
- Published: 2026-10-13T20:30:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:GENB](https://stocks.freetheai.org/symbols/NASDAQ-GENB), [OMXCOP:ZEAL](https://stocks.freetheai.org/symbols/OMXCOP-ZEAL)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Zealand Pharma A/S (OMXCOP:ZEAL) and Generate Biomedicines, Inc. (NASDAQ:GENB) have entered a strategic collaboration to design and develop AI-engineered protein therapeutics targeting obesity and other metabolic diseases. Under the agreement, Generate will receive $30 million upfront along with up to $35 million in early preclinical milestones. The total agreement value could reach nearly $1.2 billion across development, regulatory, and commercial milestones, alongside tiered royalties on potential future sales.

The partnership allows Zealand Pharma to expand its drug discovery capabilities beyond its core peptide focus into multispecific protein drugs. Generate will lead early research and lead-candidate selection using its generative artificial intelligence platform, which pairs computational design with experimental testing. Zealand Pharma will take responsibility for clinical trials, regulatory approvals, and global commercialization.

Investors will be tracking early research progress as Generate works toward candidate selection across two initial programs, with the option to add a third program later. Markets reacted cautiously on the day of the announcement, with Generate Biomedicines falling 11.45% to $12.26 and Zealand Pharma dropping 1.49% to 231.30 DKK.

## Key points

- Generate Biomedicines, Inc. (NASDAQ:GENB) will receive $30 million upfront and up to $35 million in early preclinical milestones.
- The total deal value reaches nearly $1.2 billion in potential milestones plus tiered royalties for two initial metabolic programs.
- Generate will lead drug discovery using generative AI, while Zealand Pharma A/S (OMXCOP:ZEAL) will oversee clinical trials and commercialization.
- The agreement broadens Zealand Pharma's drug discovery focus beyond peptides into multispecific protein therapeutics.

## Questions and answers

### What is the agreement between Zealand Pharma and Generate Biomedicines?

Zealand Pharma and Generate Biomedicines agreed to collaborate on developing AI-designed protein therapeutics for obesity and metabolic diseases, with Generate leading initial research and Zealand handling clinical development and commercialization.

### How much is the deal between Zealand Pharma and Generate Biomedicines worth?

Generate Biomedicines will receive $30 million upfront, up to $35 million in early preclinical milestones, and up to nearly $1.2 billion in total potential milestones, plus tiered royalties.

### What role will AI play in this drug development partnership?

Generate Biomedicines will use its proprietary generative AI platform to computationally design multispecific protein candidates and refine them through experimental testing.